This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Monitoring patients on linezolid

Authoring team

The CSM recommend that full blood counts are monitored weekly in patients who receive linezolid. The CSM also recommend close monitoring in patients who:

  • receive more than 10-14 days of treatment with linezolid
  • who receive linezolid treatment and have pre-existing myelosuppression
  • have severe renal insufficiency
  • are concomitantly being treated with other medication that may adversely affect haemoglobin levels, blood counts or platelet function

"If significant myelosuppression occurs during linezolid treatment, therapy should be stopped unless it is considered essential, in which case intensive monitoring of blood counts and appropriate management strategies should be implemented (1)."

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.